… Virus-like particle (VLP) subunit vaccines composed of the major capsid protein L1 of the
genital human papillomaviruses (HPVs) are now in Phase III clinical trials. The vaccines are …

… , nucleic acid–based vaccines, and live-vector vaccines all … , and future perspective of
several vaccines for the cure of HPV-… of therapeutic vaccines in the cure of patients infected with …

… effect can also be achieved by therapeutic vaccination of humans. … of therapeutic vaccines,
too, which target those individuals who are already infected by high-risk papillomaviruses and …

… infection these vaccines have not been found to protect against progression to neoplasia.
Attempts are being made to develop therapeutic vaccines … with therapeutic vaccine candidates …

… challenging, many therapeutic HPV vaccines have been shown … field of vaccine development,
HPV therapeutic vaccines may … therapeutic vaccines, we can foresee that HPV therapeutic …

… been extensively used in early therapeutic HPV vaccine studies. E7 alone … of therapeutic
vaccines based on E7 have been developed and tested in animal models. Most of the vaccines …

… therapeutic interventions, such as immunotherapy. To date, human papillomavirus
therapeutic vaccines are either at the preclinical level or at early phase human trials for genital …

… and high-risk human papillomavirus infection. Poster presented at: The Society for
Immunotherapy of Cancer (SITC) 34th Annual Meeting; November 6–10, 2019; National Harbor, Md. …

… Each type of therapeutic vaccine has its own advantages and disadvantages, which we
have summarized in Table 1 (also see reviews from Yang and colleagues 31,32 ). Since this …

… prophylactic vaccines have no therapeutic effects … therapeutic vaccines would have an
immediate impact on cervical cancer incidence. Prime targets for potential therapeutic vaccine …